KLDO Kaleido Biosciences Inc

Price (delayed)

$6.07

Market cap

$258.09M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.37

Enterprise value

$184.76M

Highlights
The quick ratio has soared by 153% from the previous quarter and by 22% YoY
The company's equity has surged by 113% YoY
KLDO's net income is down by 4.3% QoQ
The debt has grown by 3.1% YoY

Key stats

What are the main financial stats of KLDO
Market
Shares outstanding
42.52M
Market cap
$258.09M
Enterprise value
$184.76M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.59
Price to sales (P/S)
189.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
145.25
Earnings
Revenue
$1.27M
EBIT
-$82.29M
EBITDA
-$80.26M
Free cash flow
-$70.57M
Per share
EPS
-$2.37
Free cash flow per share
-$1.78
Book value per share
$1.69
Revenue per share
$0.03
TBVPS
$2.65
Balance sheet
Total assets
$105.03M
Total liabilities
$33.25M
Debt
$21.19M
Equity
$71.77M
Working capital
$82.16M
Liquidity
Debt to equity
0.3
Current ratio
7.38
Quick ratio
7.34
Net debt/EBITDA
0.91
Margins
EBITDA margin
-6,309.5%
Gross margin
100%
Net margin
-6,691.1%
Operating margin
-6,459.7%
Efficiency
Return on assets
-104.9%
Return on equity
-189.7%
Return on invested capital
-409.6%
Return on capital employed
-89.3%
Return on sales
-6,469.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

KLDO stock price

How has the Kaleido Biosciences stock price performed over time
Intraday
5.02%
1 week
6.68%
1 month
-23.26%
1 year
-7.75%
YTD
-33.3%
QTD
-18.41%

Financial performance

How have Kaleido Biosciences's revenue and profit performed over time
Revenue
$1.27M
Gross profit
$1.27M
Operating income
-$82.17M
Net income
-$85.11M
Gross margin
100%
Net margin
-6,691.1%
KLDO's gross profit is up by 30% QoQ
The revenue has grown by 30% from the previous quarter
The net margin has grown by 20% from the previous quarter
The operating margin has grown by 20% since the previous quarter

Growth

What is Kaleido Biosciences's growth rate over time

Valuation

What is Kaleido Biosciences stock price valuation
P/E
N/A
P/B
3.59
P/S
189.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
145.25
Kaleido Biosciences's EPS has increased by 16% YoY and by 2.9% from the previous quarter
The company's equity has surged by 113% YoY
The P/B is 62% below the last 4 quarters average of 9.0
The stock's price to sales (P/S) is 65% less than its last 4 quarters average of 512.5
The revenue has grown by 30% from the previous quarter

Efficiency

How efficient is Kaleido Biosciences business performance
KLDO's ROE is down by 29% YoY but it is up by 18% QoQ
The company's return on invested capital rose by 22% YoY but it fell by 9% QoQ
Kaleido Biosciences's ROS has increased by 20% from the previous quarter
KLDO's ROA is up by 8% from the previous quarter but it is down by 7% YoY

Dividends

What is KLDO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KLDO.

Financial health

How did Kaleido Biosciences financials performed over time
The quick ratio has soared by 153% from the previous quarter and by 22% YoY
The current ratio has surged by 153% since the previous quarter and by 19% year-on-year
The debt is 70% less than the equity
The company's equity has surged by 113% YoY
KLDO's debt to equity has dropped by 71% since the previous quarter and by 51% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.